胺素的快速和持续的抗抑郁作用是由不同的机制驱动的
Radhika Rawat1, Elif Tunc-Ozcan2, Sara Dunlop2
1Department of Neurology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Ave, Ward 10-233, Chicago, IL, 60611, USA. radhika.rawat@northwestern.edu.
Cellular and molecular life sciences : CMLS
|February 27, 2024
概括
多次胺剂量通过不同的机制增强抗抑郁药的效果. 快速效应涉及未成熟的神经元活动,而持续效应需要减少骨形态遗传蛋白 (BMP) 信号传导和增加神经发生.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 低麻醉胺剂量提供快速抗抑郁作用,但持续有效性的机制尚不清楚.
- 了解胺的双重机制对于开发长期抗抑郁药疗法至关重要.
研究的目的:
- 阐明基胺快速和持续的抗抑郁作用背后的独特的神经生物学机制.
- 研究神经发生和骨形态蛋白 (BMP) 信号传导在胺胺的长期治疗作用中的作用.
主要方法:
- 在两周内向动物施用多次亚麻醉式胺剂量.
- 评估了行为效应,不成熟的神经元活动 (海马牙状圈),神经发生标记物 (calretinin, doublecortin) 和BMP信号传递.
- 利用lentivirus操纵BMP信号在牙状环.
主要成果:
- 胺素的快速效应与不成熟神经元活动的增加相关,独立于神经发生.
- 持续的行为影响与增加的神经发生 (calretinin+, doublecortin+神经元) 和减少BMP信号传递有关.
- 阻断BMP信号阻止了胺的持续作用,但没有阻止它的快速作用.
结论:
- 胺素的快速和持续的抗抑郁作用是由单独的,暂时不同的机制调解的.
- 持续的疗效依赖于减少BMP信号,促进神经发生和增强神经元活动.
- 与胺一起准BMP信号可能会产生更持久的抗抑郁药物治疗.
更多相关视频
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
229
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
229
Parenteral Anesthetics: Overview
122
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
122
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Sedatives and Hypnotics Drugs: Miscellaneous Agents
172
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
172
Desensitization and Tachyphylaxis
1.7K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.7K
Electroconvulsive Therapy
39
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
39


